Closing ASCO: AstraZeneca’s ‘very special’ meeting, more CAR-T survival data and Pfizer’s PARP play

BioPharma Dive June 6, 2023
Ned Pagliarulo and Jonathan Gardner

Dramatically positive trial data for AstraZeneca’s Tagrisso capped an important conference for the British drugmaker, while Gilead built a stronger case for its cell therapy Yescarta.

Pascal Soriot has been attending the American Society of Clinical Oncology’s annual meeting for the past two decades.

This year’s conference, the AstraZeneca CEO told investors Monday, was “very special” for the company he has led since 2012. The British drugmaker, which not long ago lagged behind leaders in oncology like Merck & Co. and Roche, now has four blockbuster cancer medicines and a pipeline of promising drugs.

AstraZeneca’s recent successes were spotlighted at ASCO, with survival data for its lung cancer drug Tagrisso presented in a plenary session Sunday — the fifth year...

Today's Sponsors

Today's Sponsor